Posted on März 3, 2017

  • Compumedics’ Germany based, DWL business receives sales commitment, for the remainder of calendar 2017, for AUD 2.3 million (EUR 1.6 million) from its long-term distributor in China.
  • Sales commitment confirms on-going growth for DWL’s business in China representing a 7% increase over the prior year sales commitment.
  • Sales commitment to be delivered AUD 1.3million (EUR 0.9 million) before 30 June 2017 and the balance of AUD 1.0 million (EUR 0.7 million) before 31 December 2017.
  • New contract re-enforces Compumedics’ strategy to expand its core business in major global medical device markets
  • Compumedics continues to be the Number One premium supplier of sleep diagnostics and neurological research systems, and Trans-cranial Doppler (TCD) systems in China

Compumedics Limited (ASX: CMP) (“Compumedics”) – an international leader in medical devices for sleep, brain and ultrasonic blood-flow monitoring – is pleased to announce that its Germany based; DWL business has recently received a new $2.3m (EUR1.6m) sales commitment, for the remainder of calendar 2017, from its long-term distributor in China. This sales commitment confirms the on-going importance of the China market to DWL and the Compumedics Group with DWL continuing to grow its business there by a further 7% over the prior year, with this new sales commitment.

In commenting on Compumedics’ market growth in China, Dr David Burton, Chairman and CEO of Compumedics, said:

„Compumedics has a significant presence in China and has spent more than a decade with our Chinese partners, building a foundation for future growth in one of the world’s most challenging but highest growth markets. Compumedics is now the number one premium supplier of sleep diagnostic and neurological research systems in China and is carving out a similar position in TCD systems.

“As a result, Compumedics is well positioned to capture growth, across all the medical products it sells into the China market.

The Company is pleased this new sales commitment continues to build on a long and very successful relationship by continuing to deliver significant growth in this key market for the DWL business.”

About Compumedics Limited

Compumedics Limited [ASX: CMP] is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The company owns US based Neuroscan and Germany based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe and the Middle East.

Executive Chairman Dr David Burton founded Compumedics in 1987. In the same year the company successfully designed and installed the first Australian, fully computerised sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia’s Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian governments.

For further information please contact:

Dr David Burton
Executive Chairman, CEO Executive Director
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

David Lawson
Chief Financial Officer
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

Investor Relations, Media & PR enquires:

Rod North 
Managing Director
Bourse Communications Pty Ltd
Phone: +61 3 9510 8309
Mobile: 0408 670 706

Richard Allen
Oxygen Financial PR
Ph: + 61 3 9915 6341
Mob: 0403 493 049